HIF1A and breast carcinoma: Moreover, results from a randomized trial enrolling 211 breast cancer patients undergoing neoadjuvant epirubicin therapy showed upregulated expression of PHD1, PHD2 and PHD3, together with HIF-1α, VEGF and carbonic anhydrase IX (CAIX) [120].